Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Sep 20, 2024; 14(3): 91739
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.91739
Malignant pleural mesothelioma: The disdained member of thoracic oncology!
Divya Khosla, Pawan Kumar Singh, Bharath A Chhabria, Vaishali Kataria, Navneet Singh, Rakesh Kapoor
Divya Khosla, Vaishali Kataria, Rakesh Kapoor, Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Pawan Kumar Singh, Department of Pulmonary and Critical Care Medicine, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak 124001, India
Bharath A Chhabria, Department of Pulmonary and Critical Care Medicine, Ramaiah Memorial Hospital, Bengaluru 560054, India
Navneet Singh, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Co-first authors: Divya Khosla and Pawan Kumar Singh.
Author contributions: Khosla D and Singh PK contributed to conceptualization, manuscript preparation, writing, and editing and were responsible for the integrity of article; Chhabria BA and Kataria V contributed to literature search, manuscript writing, and editing; Singh N and Kapoor R reviewed and approved the manuscript.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Divya Khosla, MD, Associate Professor, Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Room No 54, Radiotherapy and Oncology Office, Ground Floor, Nehru Hospital Extension, Chandigarh 160012, India. dr_divya_khosla@yahoo.com
Received: January 3, 2024
Revised: July 17, 2024
Accepted: July 30, 2024
Published online: September 20, 2024
Processing time: 238 Days and 14.8 Hours
Core Tip

Core Tip: This review article highlights the importance of preventive measures, early and accurate detection using imaging, histopathological markers, and multidisciplinary approaches for the treatment of malignant pleural mesothelioma using surgery, systemic chemotherapy, immunotherapy, and radiotherapy. Recent novel developments in systemic treatment have expanded the therapy armamentarium, and more work needs to be done in order to frame tailored therapies for this aggressive tumor presenting in late stages and associated with a poor prognosis due to limited treatment options. It is also essential to translate these evolving treatment options into increased overall survival along with improved quality of life.